79)c 9.16 (0.12)d 5.69 (0.36)   CV % 0.83b 9.05c 1.34 6.37  Metabolic ratioe   Mean (SD) – – 0.30 (0.05) 0.31 (0.05)   CV % – – 17.80 15.76 Parameter Glimepiride M1 Glimepiride + gemigliptinf Glimepiride only Glimepiride + gemigliptinf Glimepiride only (B) Glimepiride and M1 (glimepiride metabolite)  C max (ng/mL)   Mean (SD) 231.32 (71.58) 227.05 (72.64) 29.58 (8.23) 28.26 (8.40)   CV % 30.94 31.99 27.82 29.74  AUClast (ng · h/mL)   Mean (SD) 1,086.49 (323.76) 1,104.95 (365.00) 191.85 (46.85) 189.88 (52.77)   CV % selleck chemicals llc 29.80 33.03 24.42 27.79  t max (h)   Median (min–max) 3.0 (2.0–5.0) 4.0 (2.0–5.0)

4.0 (3.0–6.0) 4.0 (3.0–6.0)   CV % 23.66 26.23 21.52 25.57  t ½β (h)   Mean (SD) 6.54 (2.30) 6.37 (2.90)g 5.87 (2.19) 6.42 (2.18)h   CV % 35.21 45.42g 37.24 33.93h  Metabolic ratioi   Mean (SD) – – 0.18 (0.03) 0.18 (0.03)   CV % – – 16.01 19.51 aRepeated administration of gemigliptin 50 mg/day for 6 days, then combination gemigliptin 50 mg + glimepiride 4 mg was administered on day 7 b n = 2; other participants were excluded selleck compound because %AUCextrapolation >20 % c n = 20; three participants were excluded because %AUCextrapolation >20 % d n = 2; others were excluded because %AUCextrapolation >20 % eLC15-0636 AUC τ,ss/gemigliptin AUC τ,ss fRepeated

administration of gemigliptin 50 mg/day for 6 days, then combination p38 MAPK apoptosis gemigliptin 50 mg + glimepiride 4 mg was administered on day 7 g n = 21; participants were excluded because %AUCextrapolation Protein Tyrosine Kinase inhibitor >20 % h n = 22; participants was excluded because %AUCextrapolation >20 % iM1 AUClast/glimepiride AUClast The mean (SD) C max,ss of gemigliptin was 80.17 (15.67) ng/mL, demonstrating a median (range) t max,ss value of 1.5 (0.5–6.0) h following repeated administration of gemigliptin only. The mean (SD) C max of glimepiride was 227.05 (72.64) ng/mL, demonstrating a median (range) t max of 3.0 (2.0–5.0) h after the single administration of glimepiride. The mean (SD) AUClast value was 1,104.95 (365.00) ng·h/mL. When glimepiride was administered with gemigliptin, the mean (SD) C max value was 231.32 (71.58) ng/mL and demonstrated a median (range) t max value of 4.0 (2.0–5.0) h. The mean (SD) AUClast value was 1,086.49 (323.76) ng·h/mL. The mean (SD) C max,ss values of LC15-0636 were 17.71 (4.45) and 17.83 (3.99) ng/mL after administering monotherapy and combined therapy, respectively. Median t max,ss values were 5.00 (range 1.0–12.0) and 4.00 (range 1.0–5.0) h, and the mean (SD) AUC τ,ss values were 233.32 (34.24) and 247.55 (36.35) ng·h/mL, respectively. The mean (SD) metabolic ratio (MR; calculated by dividing LC15-0636 AUC τ,ss by gemigliptin AUC τ,ss) was 0.31 (0.